Reducing hair growth, hair follicle and hair shaft size and hair pigmentation

Information

  • Patent Grant
  • 7985404
  • Patent Number
    7,985,404
  • Date Filed
    Friday, July 21, 2000
    24 years ago
  • Date Issued
    Tuesday, July 26, 2011
    13 years ago
Abstract
The present invention utilizes natural and/or synthetic serine protease inhibitory agents or botanical extracts containing serine protease inhibitory activity, with or without the addition of one or more isoflavones and/or additional natural extracts containing one or more isoflavones, and their ability to affect changes in mammalian hair growth, hair follicle and hair shaft size and hair pigmentation.
Description
FIELD OF THE INVENTION

This invention is related to methods and compositions effective for reducing hair growth. More specifically, the present invention is directed to methods for changing the rate of hair growth, reducing the size of the hair follicle and the hair shaft, and reducing hair shaft pigmentation, by topical application of either botanical extracts containing serine protease inhibitory activity and in particular soybean extracts such as soymilk, or mixtures and formulations of the above, combined with other active ingredients such as isoflavones.


BACKGROUND OF THE INVENTION

One main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed essentially for social and cosmetic purposes.


Many procedures are used to remove unwanted hair including shaving, electrolysis, plucking, laser and light therapies and injection of therapeutic antiandrogens. These conventional methods are not without their shortcomings. Shaving, for instance, may result in nicks and cuts in the skin's surface, may leave a perception of an increase in the rate of hair regrowth, and may also leave undesirable stubble. While electrolysis may keep an area free of unwanted hair for a prolonged period of time, the process is often expensive and painful and may further result in scarring. Not only may plucking cause pain and discomfort, but it often result in a poor removal of short hair. Several unwanted side effects, such as effects on muscularity, often accompany the use of antiandrogens. For these reasons, better methods for reducing hair growth are needed.


Pseudofolliculitis barbae is an inflammatory hair disorder, most commonly found on the beard area. Inflammatory follicular papules result when hair tips penetrate into the skin rather than passing through the follicular orifice. This process is extremely common in black men because their hairs are frequently curly, exiting the skin at an acute angle. Close shaves, particularly with a razor blade, predispose them to pseudofolliculitis barbae. The most effective treatment available is to allow the hairs to grow well beyond the skin surface. Such a treatment is often not desired.


Hirsutism is a relatively frequent condition affecting about 4% of women. Facial hirsutism often interferes with personal and work activities, and temporary hair removal is a major component in the management of hirsute patients. Shaving is the most frequently used temporary method for facial hair, as plucking, waxing and depilatories are more difficult to tolerate and care must be taken to avoid folliculitis, pigmentation, and scarring. Cosmetic cover-ups are usually used to hide cuts and stubble and electrolysis and thermolysis may be used for permanent hair removal when affordable.


An alternative or complementary desired approach to hair removal, would be a method to reduce hair growth, reduce hair follicle and hair shaft size and reduce hair shaft pigmentation. Such an approach could reduce the visibility of existing hair, making it softer and lighter. When combined with other methods of hair removal such a method could enhance and prolong the removal effect, and reduce the need and frequency of hair removal. Long term use of such an approach could lead to attenuated, soft, pigmentation-reduced hair growth, that is less visible and does not require the use of other removal methods.


Reduced hair growth is desired in the axilla area (fossa axillaris), where deodorants and anti-perspirants are used to control odor trapped within the axillary hairs. It would be desired to have products for under-arm use, which combine deodorant or anti-perspirant activities with reduced hair growth activity.


African type hair is unique in its morphology—a kinky hair shaft with variations in diameter. This complex shaft structure creates the need for specialized grooming products and procedures to ensure that the African type hair maintains cosmetic desired properties.


It is desired to have products that reduce this complexity and make the African type hair more manageable, improving its appearance.


It would be desirable to provide a method for chemically or naturally affecting hair growth, hair follicle and hair shaft size and hair shaft pigmentation, which does not cause unwanted side effects to the user.


SUMMARY OF THE INVENTION

In accordance with the present invention, we have found compositions and methods for affecting changes in mammalian hair growth, hair follicle and hair shaft size and hair pigmentation by topically applying to the skin of a mammal an effective amount of a topically active composition comprising protease inhibitors, botanical extracts, and in particular legume extracts including, but not limited to, soymilk, for a period of time sufficient to affect hair growth, hair follicle and hair shaft size and hair shaft pigmentation. Such topically active compositions may be further combined with other active ingredients including, but not limited to, synthetic or naturally occurring isoflavones, to enhance the desired effects on hair growth and pigmentation.


The compositions and methods of this invention provide a unique, convenient means for delaying hair growth, reducing hair follicle and hair shaft size and hair shaft pigmentation, by using serine protease inhibitors, botanical extracts of the legume family, and in particular, but not limited to, soymilk, containing serine protease inhibitory activity, and their combinations with isoflavones.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will be more fully understood and further advantages will become apparent when reference is made to the following detailed description of the invention and the accompanying drawings in which:



FIG. 1: A photograph of control and soymilk treated C57Bl/6 mouse hair (high magnification).



FIG. 2: Histological sections of control and soymilk treated C57Bl/6 mouse hair follicles at day four of the hair cycle.



FIG. 3: Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at day seven of the hair cycle, high and low magnifications.



FIG. 4: Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at day 18 of the hair cycle.



FIG. 5: Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at day 21 of the hair cycle.



FIG. 6: Histological sections of control, soymilk, and soymilk-derived proteins-treated C3H mouse hair follicles (High magnification) at day seven of the hair cycle.



FIG. 7: Histological sections of control, soymilk, and soymilk-derived proteins-treated C3H mouse hair follicles (lower magnifications) at day seven of the hair cycle.



FIG. 8: Histological sections of control and soymilk-treated C3H mouse hair follicles at day 21 of the hair cycle.



FIG. 9: A photograph of control and soymilk-derived proteins treated C3H mouse hair (high magnification).



FIG. 10: Histological sections of control and soymilk-derived proteins-treated C57Bl/6 mouse hair follicles (High magnification) at day eight of the hair cycle.



FIG. 11: A graph demonstrating the trypsin inhibitory activity of soymilk.



FIG. 12: Western blot of C57Bl/6 mouse skins throughout the hair cycle, demonstrating reduced tyrosinase and TRP-1 protein levels following soymilk treatment.



FIG. 13: Photographs of untreated and soymilk treated sides of human face, treated with soymilk daily for four weeks.



FIG. 14: Quantitative analysis of hair follicle dimensions with and without soymilk treatment.



FIG. 15: Photographs of human leg hair following five weeks of soymilk treatment on one leg.



FIG. 16: Photographs of control, soymilk, and isoflavone-enriched soymilk treated C57Bl/6 mouse hair (high magnification).



FIG. 17: Histological sections of control, soymilk, and isoflavone-enriched soymilk treated C57Bl/6 mouse skins at day 15 of the hair cycle, documenting the thickness and color of the hair shafts.



FIG. 18: Photograph of C57Bl/6 mouse hair after three weeks of treatment with various soymilk and isoflavones formulations.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

As used herein, “mammal” shall mean any member “of the higher vertebrate animals comprising the class Mammalia,” as defined in Webster's Medical Desk Dictionary 407 (1986), and includes but is not limited to humans. As used herein “(%, w/v)” shall mean grams of a given component per 100 ml of the total composition.


Topically active agents suitable for use in the composition of the present invention include protease inhibitors and natural plant extracts having protease inhibitory activity and mixtures thereof. Preferred protease inhibitors are serine protease inhibitors, and in particular Soybean Trypsin Inhibitor (“STI”) and the soybean-derived Bowman Birk Inhibitor (“BBI”). Preferred botanical extracts are of the legume family and in particular bean extracts, such as soymilk. Preferably, the protease inhibitors are present in an amount, based upon the total volume of the composition of the present invention, of from about 0.0001% (w/v) to about 20% (w/v), and more preferably from about 0.001% (w/v) to about 5% (w/v). Preferably, botanical aqueous extracts such as soymilk are present in an amount of 10-99% (v/v), and more preferably from 50-99% (v/v).


This invention also relates to compositions and methods for affecting changes in mammalian hair growth, hair pigmentation and hair shaft and follicle size, comprising topically applying to skin of a mammal an effective amount of a topically active composition comprising one or more compounds derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae.


We have unexpectedly found that when topically active agents such as described above, and in particular soymilk or soymilk containing formulations, are enriched with isoflavones, and in particular soybean-derived isoflavones, the inhibitory effect on hair growth, hair dimensions and hair pigmentation is enhanced.


Preferably, the isoflavones are present in the botanical aqueous extracts such as soymilk in an amount of 0.000005-15% (v/v), and more preferably from 0.00001-10% (v/v).


If the delivery parameters of the topically active pharmaceutical or cosmetic agent so require, the topically active composition of the present invention may be further comprised of a pharmaceutically or cosmetically acceptable vehicle capable of functioning as a delivery system to enable the penetration of the topically active agent into the hair follicle and the skin.


The pharmaceutical or cosmetic composition may be optionally combined with other ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, depigmenting agents, anti-aging agents, hair removal agents, hair styling agents, sunscreens surfactants, foaming agents, conditioners, humectants, fragrances, colorants, viscosifiers, buffering agents, preservatives, and the like and mixtures thereof. These will be combined in an amount which will not affect the serine protease inhibitory activity, in order to produce cosmetic or pharmaceutical products such as, non-exclusively, essences, creams, lotions, pastes, gels, powders, patches or injectables and the like for the reduction of hair growth, hair size and hair pigmentation.


The compositions of this invention may be applied prior to, concurrently with or after other active ingredients or compositions to enhance their effect. For example, the compositions of this invention may be applied in conjunction with one or more products whose purpose is to facilitate the removal of hair to actually remove hair, reduce hair visibility, improve hair style or improve hair management. The compositions of this invention may be applied topically prior to, during or following hair removal. They may be applied topically concurrently with one or more of the following group: depilatory agents, shampoo, hair conditioner, styling gel, hair care products, waxing products, shaving products, hair-removal products, after-shave products, deodorant, anti-perspirant, electrolysis, laser hair removal, light-induced hair removal, mask or bath additives.


The compositions of this invention may be applied daily for at least four to eight weeks, by which an effect upon the appearance of hair should be observed. Application may be continued as long as desired to maintain the condition of the hair. Daily application to the face may mitigate the condition of pseudofolliculitis barbae and/or hirsutism; application to the axillary area may reduce hair growth under the arms and application to the scalp and hair may assist in managing and styling African-type hair.


The topically active pharmaceutical or cosmetic composition should be applied in an amount effective to effect changes in mammalian hair growth, hair follicle and hair shaft size and hair shaft pigmentation. As used herein “amount effective” shall mean an amount sufficient to cover the region of skin surface where a delay in hair growth and hair pigmentation and reduced hair size are desired. Preferably, the composition is applied to the skin surface such that, based upon a square cm of skin surface, from about 2 μl /cm2 to about 500 μl /cm2 of topically active agent is present when a delay in hair growth, hair size and hair pigmentation is desired.


We have unexpectedly found that when topically active agents, such as soymilk, or isoflavone-enriched soymilk are topically applied to an animal's skin, a significant delay in hair growth, hair follicle and hair shaft size and hair shaft pigmentation was achieved. We further believe that since the hair growth cycle for humans is often slower than that for mice, it is further likely that the hair growth delay in humans would be considerably longer than in mice.


The invention illustratively disclosed herein suitably might be practiced in the absence of any component, ingredient, or step which is not specifically disclosed herein. Several examples are set forth below to further illustrate the nature of the invention and the manner of carrying it out. However, the invention should not be considered as being limited to the details thereof.


EXAMPLES
Example 1
Depilation of Test Subjects in the Mouse System

C57BI/6 or C3H mice (male and female) were obtained from Charles River (Kingston, NY), at 8-10 weeks of age and were in the resting (telogen) phase of their respective hair cycle. Hair growth was induced by wax depilation (plucking) of each respective animal's back fur according to the procedure set forth in Stenn, et al., “Glucocorticoid Effect on Hair Growth Initiation: A Reconsideration,” 6 Skin Pharmacol., 125-134 (1993). In C57Bl/6 and C3H mice, 8-10 weeks old, the growth phase (anagen) starts synchronously in all hair follicles at the time of depilation. As illustrated in Table 1, the following observations were noticed at the induction site:









TABLE 1







Observations at Induction Site











Morphological and Histological



Days Post-Induction
Observations at the induction site







1-2 (early anagen)
new follicle starts to grow



3 to 4
hair follicles were fully developed,




but the hair shafts were not yet




visible



7 to 8 (late anagen)
each mouse had very dark skin; their




hair shafts are histologically




visible



11-12
the hair shafts started to penetrate




through the epidermis.



14
each mouse was covered with short




hairs



19
the regression of the follicle




(catagen) was observed histologically



21 to 25
the hair follicle is back to resting




phase.










As shown in Table 1, the hair growth was visible several days after depilation as the pink skin of the animal began to darken. This is likely due to hair pigmentation in the shaft since the C57BI/6 and C3H mice contained melanocytes only in the hair follicles and not in the dorsal epidermis. Similar hair growth pattern was documented in our international application No. PCT/US 97/11033, when chemical depilation using commercially available products was performed.


Since the murine hair cycle varies not only between strains, but also amongst individual animals, the status of the hair cycle was analyzed in each animal on study. A 2 cm by 1 cm skin sample was isolated from each mouse with scissors, fixed with a 10% buffered formalin solution having a pH of about 6.9-7.1 at 25° C. (Stephens Scientific), and then formed into a paraffin block according to well-known procedures. The block was then microtomed, and sections were stained with H&E or Fontana-Mason stain. Sections were examined histologically in order to verify the phase of the hair cycle, the size of the hair follicle and hair shaft and the level of hair pigmentation, using procedures well known in the art. Hair length was assessed visually, and by using a low magnification (×8) dissecting microscope.


This Example, as well as the one described in our international application No. PCT/US 97/11033, shows that the hair growth cycle for C57BI/6 and C3H mice averaged about 25 days and reports similar timing of hair follicle and shaft development regardless of the method used for depilation.


Example 2
Preparation of Soymilk and Soymilk Formulations

One way to make soymilk is to soak the soybeans in deionized or purified water for several hours, and grind them after they were fully hydrated, with the addition of small quantities of water. (The grinding process allows the soybean milk to be extracted). After collection, the soybean milk may be filtered to remove any residual parts of the bean husk. The soymilk used in the formulations described below can be fresh soymilk as described above, or may be made from soybean powder and water. The soybean powder is milled from soybeans and may also be lyophilized, spray dried, or freeze-dried and the resulting soymilk may or may not be filtered. Such prepared soymilk may have from about 1 to about 90% by weight dry soybean powder. Another example is the use of soymilk powder, made from lyophilized, spray dried or freeze-dried soymilk, with the addition of water and finished with or without filtration or homogenization. Other methods of soybean extraction could also be used to create the active ingredients in the formulations described below. For example, the active ingredients could be extracted from ground soybeans using ethanol/water mixtures, followed by the removal of the ethanol from the extract, in such ways that the serine protease inhibitory activity of the soybean will be retained, and preferably that the protein STI will remain intact.


The soy products useful in this invention may be produced from all soybean species, regardless of their geographic origin, sun exposure, harvest time and the like. However, specific strains, geographic origins or growth conditions might be preferred. For example, but not limiting to, soybean strains particularly rich in its Soybean Trypsin Inhibitor (STI) content or in isoflavone content, or growth conditions that result in STI or isoflavone enrichment in the bean, might be preferred. It should be noted that the soy products useful in the compositions of this invention have a distinctive odor, which may be tolerable in some cultures, but is undesired in others. If necessary, the odor of the compositions of this invention may be reduced by using soybean products derived from specific strains of soybeans known to produce reduced-odor, including, but not limited to, lipoxygenase-2-deficient beans and those having modified sugar profile, and the like. A process to reduce oxygen levels in the formulation may also reduce the odor. Various masking agents or fragrances may also be used to mask the odor.


The compositions of this invention may further comprise surfactants, moisturizers, humectants, conditioners, fragrances, colorants, preservatives, anti-oxidants, depigmenting agents, hair removal agents, anti-aging agents, sunscreens, foaming agents, cosmetic adjuvants, buffering agents or mixtures thereof.


The compositions of this invention may be left on the skin for a period sufficient to effect changes. For example, the compositions of this invention may be applied to the skin daily treatment for at least about four weeks, more preferably, the composition should applied daily for at least eight weeks.


Another method according to this invention is a method to reduce or prevent pseudofolliculitis barbae. Daily application of the compositions of this invention may reduce or prevent this condition. The compositions of this invention may also be applied daily to the axilliary area to reduce hair growth. Furthermore, the compositions of this invention may be applied daily to the scalp to style and improve management of African type hair.


As shown in our co-pending U.S. patent application Ser. No. 09/110,409, numerous soymilk-based formulations could be used to reduce pigmentation. All these formulations could also be used to reduce hair growth. Some particularly preferred examples of soymilk formulations and soymilk formulations containing isoflavones are shown in table 2 below. An example for an isoflavones preparation that could be used in this invention is Flavosterone SE from Ichimaru, Japan, which contains about 0.1% pure isoflavones. In all these formulations, soymilk could be replaced with the appropriate quantities of soybean powder or soymilk powder and water.









TABLE 2





Soymilk Essence formulations:


Soybean Essences

























1
6
8
21
22
23
24
25
26





Soymilk
 87.42%
 89.04%
96.09%
96.05%
96.05%
95.70%
94.40%
94.40%
92.40%


Phenoxyethanol
  0.73%










Phenoxyethanol and Parabens

 1.00%
 1.00%
 1.00%
 1.00%
 1.00%
 1.00%
 1.00%
 1.00%


Glycerin
  2.50%
 2.50%









Cyclomethicone
  2.00%










Aluminum Starch Ocetyl Succinate
  0.75%










Sucrose Cocoate
  1.00%
 1.00%









PEG-6 Capric/Caprylic Triglycerides
  3.00%
 3.00%









Disodium EDTA
  0.10%
 0.10%



 0.05%
 0.05%
 0.05%
 0.05%


Polyacrylamide/Laureth-7/C13-14
  2.50%
 2.75%
 2.90%
 2.90%
 2.90%
 3.20%
 3.50%
 3.50%
 3.50%


Isoparrafin











Ascorbic Acid

 0.01%






 1.00%


Butylated Hydroxytoluene

 0.10%
 0.01%
 0.05%
  0.05%
 0.05%
 0.05%
 0.05%
 0.05%


Polysorbate 20

 0.50%









Lactoferrin






 1.00%
 1.00%
 1.00%


Tocopherol








 1.00%


TOTAL
100.00%
100.00%
  100%
  100%
  100%
  100%
  100%
  100%
  100%






27
28
29
30
31
32
33
34
35





Soymilk
90.70%
94.70%
85.70%
90.70%
93.70%
94.70%





Phenoxyethanol and Parabens
 1.00%
 1.00%
 1.00%
 1.00%
 1.00%
 1.00%
 1.00%
 1.00%
 1.00%


Glycerin
 5.00%










Disodium EDTA
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%


Polyacrylamide/Laureth-7/C13-14
 3.20%
 3.20%
 3.20%
 3.20%
 3.20%
 3.20%
 3.20%
 3.20%
 3.20%


Isoparrafin











Ascorbic Acid











Butylated Hydroxytoluene
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%
 0.05%


Deionized Water






90.70%
90.70%
85.70%


Dow Corning 200 Fluid

 1.00%









Flavosterone SE


10.00%
 5.00%
 2.00%
 1.00%





Soymilk Power






 5.00%




Soybean Extract using Ethanol/Water







   5%
  10%


Mixture











TOTAL
  100%
  100%
  100%
  100%
  100%
  100%
  100%
 100%
  100%









Example 3
Preparation of Topically Active Compositions Containing Soybean Derived Protease Inhibitors

Soybean trypsin inhibitor (STI) and Bowman-Birk inhibitor (BBI), from Sigma-Aldrich Corporation were mixed into a 0.1M phosphate buffered saline (PBS, Gibco-BRL, Gaithersburg, MA), pH 7.4, in concentrations of 1% to 0.001% (w/v). Four volumes of the resulting solutions were then mixed with 1 volume of (100 mg/ml) liposomes vehicle, which was prepared by the methods described in Niemiec et. al, in order to yield the topically active composition. Non-ionic liposomes preparations, such as those disclosed in Niemiec et al., “Influence of Nonionic Liposomal Composition On Topical Delivery of Peptide Drugs Into Pilosebaceous Units: An In Vivo Study Using the Hamster Ear Model,” 12 Pharm. Res. 1184-88 (1995) (“Niemiec”), which is incorporated by reference herein in its entirety, are well known in the art, and are described our U.S. patent application Ser. No. 09/110,409. GDL liposomes were prepared as set forth in Niemiec, et al., above, with the exception of the following changes: the non-ionic liposomal formulation contained glycerol dilaurate (Emulsynt GDL, ISP Van Dyk)/cholesterol (Croda)/polyoxyethylene-10-stearyl ether (Brij76, ICI)/polyoxyethylene-9-lauryl ether, as at ratio of 37.5:12.5:33.3:16.7. Either PBS or Hepes buffer, 0.05M, pH 7.4 (Gibco-BRL of Gaithersburg, Md.) were used as the aqueous phase in the preparation of the liposomes.


Example 4
Soymilk Delays Hair Growth and Reduce Hair Follicle and Hair Shaft Size and Hair Shaft Pigmentation

C57Bl/6 mice were induced for a new hair cycle as described in Example 1, and treated daily with soymilk.


ANIMALS were observed daily for their hair growth pattern, and skin biopsies were taken at important time points of the hair cycle. As a result of soymilk treatment the hair growth of the treated mice was delayed, and their hairs were visibly thinner, and smoother to touch. Treated mice did not show skin darkness at days 7-8 of the hair cycle, as expected, and hair shafts were not visible at days 11-12 as in the control animals. In average, the hair cycle of the soymilk treated mice was delayed by 3-6 days. FIG. 1 is a picture of the mice fur, showing the difference in hair appearance, color, size and thickness following soymilk treatment.


Histological examination of the biopsied skin samples confirmed these observations. As shown in FIG. 2 by Fontana-Mason (F&M) staining, at day four of the hair cycle the untreated hair follicle is fully developed, as expected, containing all the cellular layers and pigment deposition. In contrast, the soymilk treated sample, (shown at same magnification), shows a smaller and not as fully developed hair follicle, with no pigment deposition.



FIG. 3 shows two sets of histological sections stained with F&M, of lower and higher magnification. These sections are from day seven of the hair cycle. The upper panel shows that soymilk treated skin has smaller, shorter, and less pigmented hair follicles than the untreated control. The lower panel shows a higher magnification of the follicles, further demonstrating the difference in hair follicle and hair shaft size and pigmentation following soymilk treatment.



FIG. 4 shows low magnification of F&M stained skin sections at day 18 of the hair cycle. At this magnification it is obvious that soymilk treatment results in reduced hair follicle size, which leads to reduced hair shaft length and thickness, and reduced total pigment deposition within the treated follicles.



FIG. 5 shows skin sections at day 21 of the hair cycle, with two magnifications. The upper panel demonstrates that the control animals were in the catagen stage, when hair follicles are regressing. Soymilk treated follicles, on the other hand, had already completed the catagen stage, as they are shown in telogen, the resting stage. This indicates that not only the hair cycle was delayed following soymilk treatment, it was also prematurely terminated. The lower panel demonstrates the catagen control follicle and the shorter, telogen (resting) soymilk-treated follicle using higher magnification.


Example 5
The Effects of Soymilk on Hair Growth, Size and Pigmentation are Reproducible in C3H Mice

In order to verify that the effect of soymilk on hair growth is not specific to C57Bl/6 mice, we repeated the experiment described in Example 4 using the brown haired (Agouti) C3H mice. The results of these experiments were similar both visually and histologically. Soymilk delayed hair growth and reduced hair follicle and hair shaft size and pigment deposition in the C3H mice.


Histological analysis confirmed these visual observations. As shown in the upper panel of FIG. 6, using F&M staining, at day seven of the hair cycle soymilk treated follicles are smaller and accumulate less pigment than untreated controls. The upper panel of FIG. 7 (F&M staining) shows a lower magnification of the same skin sections, demonstrating the thinner and less pigmented follicles following soymilk treatment.



FIG. 8 shows F&M stained skin sections at day 21 of the hair cycle. As shown for the C57Bl/6 mice, following soymilk treatment the hair cycle terminates prematurely. Soymilk treated follicles are in the resting state, while untreated control follicles are still in catagen.


Example 6
The Effects of Soymilk and Soybean Derived Serine Protease Inhibitors on Hair Growth, Size and Pigmentation

In search for a mechanism to explain the effect of soymilk on hair growth, we tested the effect of the soymilk-derived serine protease inhibitors, STI and BBI.


We had shown earlier that these proteins induce depigmentation in skin, by affecting the PAR-2 pathway (U.S. patent application Ser. No. 09/110,409).


The experiments described in Example 4 were repeated using STI, BBI, and soymilk. STI and BBI were used in a PBS-liposome vehicle as described in Example 3. Visual observations throughout the hair cycle confirmed that both STI and BBI could delay hair growth and reduce hair follicle and hair shaft size, similar to soymilk (see hair pictures in FIG. 9). Using high concentrations of STI or BBI, the effect on hair growth and pigmentation was substantial.


Histological analysis confirmed these finding. As shown in FIG. 6, at day seven of the hair cycle 1% of STI and 1% of BBI reduce hair follicle and hair shaft size and hair shaft pigmentation in C3H mice. FIG. 7 shows lower magnification sections of the same day into the hair cycle, demonstrating smaller hair follicles and hair shafts and reduced pigmentation, relative to untreated control, with soymilk, STI or BBI treatment. FIG. 10 shows that STI and BBI have the same effect in C57Bl/6 mice too, demonstrating smaller and less pigmented follicles. Taken together, this example shows that STI and BBI are soybean-derived serine protease inhibitors, found in soymilk, that could delay hair growth, reduce hair follicle and hair shaft size and reduce hair pigmentation. STI and BBI could represent a part of the soymilk ingredients that affects hair growth.


In order to support the hypothesis that STI and BBI in soymilk are involved in the hair growth effects described above, we tested soymilk for its serine protease inhibitory activity. An enzymatic assay was performed using “Enzchek”, a protease digestion fluorescent test system made by Molecular Probes of Eugene, Oreg. Using 100 units of trypsin (from Sigma chemicals, St. Louis Mo.) the test system produced fluorescence reading of about 1100 units. This reaction was inhibited with increasing concentrations of STI, as expected from a known trypsin inhibitor. Serial dilutions of soymilk were tested in this assay, and found to inhibit trypsin activity. As shown in FIG. 11, soymilk exerts trypsin inhibitory activity similar to about 0.2% of pure STI. This suggests that soymilk could exert its hair growth effect, at least in part, by STI and BBI.


Example 7
Soymilk Induces Changes in Tyrosinase and TRP-1 Protein Expression

The histological analyses of soymilk treated skin samples described in the examples above show dramatic reduction in pigment deposition within the hair follicle. To further understand the mechanism of soymilk-induced depigmentation, we studied tyrosinase, the key enzyme in melanogenesis and Tyrosinase-Related Protein-1 (TRP-1), the enzyme that stabilizes tyrosinase. C57Bl/6 and C3H mice were treated as described above, and samples were collected throughout the study for protein analysis. Protein extraction and Western blot analysis were performed using standard procedures, such as the one described in Current Protocols in Cell Biology, Edited by Juan S. Bonifacino et al. Chapter 6: Electrophoresis and Immunoblotting. Copyright 1999 by John Wiley & Sons, Inc., which is incorporated herein by reference in its entirety. An example of one such study is shown in FIG. 12.


Equal amounts of skin-extracted proteins were probed with the anti-tyrosinase antibody “anti PEP1”, and with the anti-TRP-1 antibody “anti PEP7” which are described in Jimenez, M., Kameyama, K., Maloy, W L, Tomita Y., and Hearing, V. Mammalian tyrosinase: biosynthesis, processing and modulation by melanocyte stimulating hormone. Proc. Natl. Acad. Sci. USA (1988), 85:3830-34, and Jimenez, M., K., Maloy, WL, and Hearing, V. Specific identification of an authentic tyrosinase clone. J. Biol. Chem. (1989) 264:3397-3403, which are incorporated herein by reference in their entirety.


As shown in FIG. 12, The expression of Tyrosinase and TRP-1 proteins is dramatically affected by soymilk treatment. Tyrosinase and TRP-1 levels are reduced, and the duration of the expression is shortened. These two factors affect overall hair pigmentation, which is reduced due to the reduced level and shorter duration of melanogenesis.


Example 8
Soymilk Reduces Human Facial Hair Length and Thickness

An individual male with dark facial hair who shaves daily was treating the right side of his face with soymilk, immediately after shaving, for five weeks. By the third week, and more noticeably by the forth week, the hair of the treated side was visually lighter and felt smoother to touch. Digital pictures at different magnifications were taken throughout the treatment period, using Hi-Scope. These pictures clearly demonstrate the reduced size and thickness of the hair shafts at the treated side. An example of such pictures is shown in FIG. 13, demonstrating the difference in hair shaft thickness and density at four weeks of treatment. Since both sides of the face were shaved at the same time, and pictures of both sides were taken at the same time, the difference in length of the facial hair indicates slower growth rate at the treated area.



FIG. 14 shows a computerized image analysis of the facial hair length, thickness and total area, following four weeks of soymilk treatment. All images were analyzed with Image Pro Plus 3.0 software (Media Cybernetics, Silver Spring, MD). Data are presented as average of 180 hair shafts of each side of the face, with standard deviation (SigmaPlot® 5.0, SPSS Science, Chicago, Ill.). Statistical analysis was performed using SigmaStat® 2.0 (SPSS Science) software, demonstrating a statistical significant difference in all measured parameters, following soymilk treatment.


Example 9
Soymilk Reduces Human Legs Hair Length and Thickness

Hair was wax-depilated of two symmetrical areas of the medial part of the legs, below the knee, in one individual. One leg was treated daily, for four weeks, with soymilk. Visual observations indicate slower hair growth on the treated site. Hair shafts were reduced in number and were shorter and thinner than those of the untreated site, as shown in FIG. 15. These observations further confirm the effect of soymilk on hair growth. Examples 8 and 9 together confirm that the effect of soymilk on human hair growth is not related to the method of hair removal or to the body part being treated.


Example 10
Soymilk Formulations Enriched with Isoflavones are Preferred to Soymilk Formulations in Reducing Hair Growth and Pigmentation

The experiments described in Example 4 were repeated, using two formulations described in Table 2 above, Soymilk Essence 23 which is a soymilk-based formulation, and soymilk Essence 30 which is identical to Soymilk Essence 23 except the addition of 5% of a 0.1% isoflavones extract. As shown in FIG. 16, mice treated with Soymilk essence 23 show reduced hair growth and nicer hair appearance. This effect was more pronounced with the use of soymilk Essence 30, demonstrating that isoflavone-enriched soymilk formulations are superior to soymilk formulations in reducing hair growth. FIG. 17 shows histological skin sections of the treated mice, at day 15 of the treatment. The hair shafts documented in these sections clearly demonstrate the reduction in hair shaft dimensions, the reduced level of pigmentation within the hair shaft, and the increased smoothness of the hair shaft following the Soymilk Essence treatments.


Example 11
Soymilk Formulations Enriched with Isoflavones are Preferred to Isoflavone Formulations Which are Effective in Reducing Hair Growth and Pigmentation.

The experiments described in Example 4 were repeated, using formulations described in Table 2 above, of soymilk essence with or without increasing concentrations of isoflavones. These Soy Essence formulations were compare to similar formulations, where the soymilk component only was replaced with water.


These three sets of formulations (Soy Essence, isoflavones, Soy Essence containing additional isoflavones) were prepared to test the possibility that isoflavones might be sufficient for the effect observed on hair growth. FIG. 18 shows the C57Bl/6 mouse hair following three weeks of topical treatment, as described in example 4. Both untreated control mice and placebo treated mice have long and less “ordered” hair. Soymilk Essence 23 reduces hair growth and leads to a nicer appearance, as described earlier in this application.


Soymilk Essence formulations containing 1, 5 and 10% of a 0.1% isoflavones containing extract result in a superior effect on hair growth. However, formulations containing isoflavones but no soymilk demonstrate milder, and not as superior effect as when combined with soymilk. This example demonstrates that soymilk formulations containing isoflavone could reduce hair growth. This example further demonstrates that soymilk formulations containing isoflavones reduce hair growth to a higher degree than formulations containing isoflavones alone.


Example 12
Soy Essence Formulations Affect Human Hair Growth

The efficacy and irritancy potential of Soymilk Essence 23 and 30 compared to a placebo formulation were examined in a blinded placebo-controlled four-week test with twelve pre-menopausal female panelists ages 29 to by evaluations by the study investigator, self-assessment by panelists and Hi-scope image analysis. Panelists signed an Informed Consent and were instructed about study procedures and expectations and were asked to shave that night. At the baseline visit the following day, two test lotions were distributed to each panelist (Day 1), a placebo lotion and either soymilk Essence 23 or 30. The lotions were randomly assigned to either the right leg or left leg. The test lotions and placebo were used on the respective legs for the duration of the study with no other lotions used on the lower legs. Panelists were instructed to apply the test lotions twice daily, morning and evenings and were also instructed to try to refrain from shaving their lower legs until after each weekly evaluation. On evaluation days, the investigator visually inspected the panelists' legs for any clinical signs of irritation and compared legs for hair growth attenuation. Self-assessment questionnaires were completed by panelists at each evaluation time point (Weeks 1, 2, 3 and 4). In addition, Hi-scope images (2.5 cm in diameter for each image, KH-2400R, Hirox) were obtained at each time point using a MX-MACROZ lens (Hirox).


No panelists dropped from the study for any product-related reason. No signs of irritation were seen in any of the study panelists at any time point, nor was any irritation reported when self-assessed by panelists at any time point during the study.


For the purpose of hair counts all hair, including “stubble”, were counted in the given 2.5 cm field for each panelist at each time point. Results showed a decrease in lower leg hair counts by week 5 for Soymilk Essence 30 and by week 4 for Soymilk Essence 23. The placebo treated legs did not show a change in mean leg hair counts throughout the study although the standard deviations were large. The growth rate was calculated by dividing the length of time (in days) since the panelist last shaved, by the average length of leg hairs for that panelist, which was calculated from the hi-scope images using Image Pro Plus analysis for each panelist at each test site. The results are documented in Table 3, demonstrating that both Soymilk Essences 23 and 30 treatments resulted in reduced hair growth rate compared to placebo.









TABLE 3







Mean leg hair growth rates following Soymilk Essence or placebo


treatment













Soymilk
Soymilk



Week
Location
Essence 30
Essence 23
Placebo





0
Upper
0.211 (±0.07)
0.184 (±0.07)
0.243 (±0.07)


(baseline)
Lower
0.248 (±0.08)
0.191 (±0.06)
0.235 (±0.09)


1
Upper
0.216 (±0.05)
0.153 (±0.03)
0.211 (±0.06)



Lower
0.178 (±0.08)
0.213 (±0.03)
0.188 (±0.07)


2
Upper
0.232 (±0.11)
0.181 (±0.04)
0.221 (±0.07)



Lower
0.236 (±0.12)
0.195 (±0.07)
0.217 (±0.09)


3
Upper
0.241 (±0.06)
0.185 (±0.09)
0.285 (±0.13)



Lower
0.213 (±0.10)
0.147 (±0.04)
0.253 (±0.12)


4
Upper
0.234 (±0.07)
0.209 (±0.11)
0.211 (±0.09)



Lower
0.194 (±0.05)
0.208 (±0.07)
0.220 (±0.04)









Results from panelists' self-assessment questionnaires showed that panelists felt that the test lotions attenuated hair growth and softened the feel of leg hair, compared to the placebo lotion. Panelists felt that the hair felt less coarse and less stubbley. The majority of the panelists believed that the test lotions were attenuating leg hair growth or altering the texture of the hair so that it felt smoother and less coarse. Hi Scope analysis further demonstrated that the hair re-growth following treatment with Soymilk Essence 23 or 30 seemed to be growing in the same direction and was more uniform in shape, texture and appearance. In contrast, the hair that re-grew on the placebo-treated legs grew in different directions, differing in length, angle of growth and thickness.


This Example clearly demonstrate the effect of soymilk formulations in delaying and reducing hair growth, and enabling the growth of softer, less coarse and more managed and directionally-organized hair.

Claims
  • 1. A method of reducing hair growth and reducing hair follicles and hair shaft size in mammalian hair in need thereof, comprising topically applying at least once daily for at least seven days from the beginning of a hair cycle to hair follicles on the skin of a mammal an effective amount of a hair growth-reducing and hair follicle and shaft size reducing topically active composition comprising one or more compounds derived from one or more of a botanical family leguminosae, wherein said compounds comprise at least one serine protease inhibitor consisting essentially of soybean trypsin inhibitor, wherein after daily application for at least seven days from the beginning of the hair cycle, hair growth, hair follicles and hair shaft size are reduced in comparison with the appearance of hair prior to applying said composition.
  • 2. The method of claim 1 wherein said at least one serine protease inhibitor is present in an amount, based upon the total volume of the topically active composition, of from about 0.0001% (w/v) to 20% (w/v).
  • 3. The method of claim 2 wherein the at least one serine protease inhibitor is present in an amount, based upon the total volume of the topically active composition, of from about 0.001% (w/v) to about 5% (w/v).
  • 4. The method of claim 1 wherein one of said changes is a delay in hair growth, reduced hair follicle and hair shaft size and reduced hair pigmentation.
  • 5. The method of claim 1 wherein said topically active composition further comprises a pharmaceutically or cosmetically acceptable vehicle.
  • 6. The method of claim 1 wherein said topically active composition further comprises one or more isoflavones.
  • 7. The method of claim 6 wherein said topically active composition further comprises a pharmaceutically or cosmetically acceptable vehicle.
  • 8. The method of claim 1 wherein said topically active compositions further comprises natural extracts containing one or more isoflavones.
  • 9. The method of claim 1 wherein said composition is applied topically in conjunction with one or more products whose purpose is to either facilitate the removal of hair or actually remove hair or reduce hair visibility or improve hair style or improve hair management.
  • 10. The method of claim 1 wherein said composition is applied topically, before or following hair removal.
  • 11. The method of claim 1 wherein said composition is applied topically during hair removal.
  • 12. The method of claim 1 wherein said composition is applied topically in conjunction with one or more of the group consisting of: depilatory agents, shampoo, hair conditioner, styling gel, hair care products, waxing products, shaving products, hair-removal products, after-shave products, deodorant, anti-perspirant, laser hair removal light induced hair removal, mask, and bath additives.
  • 13. The method of claim 1 further comprising leaving said composition on said skin for a period sufficient to effect changes.
  • 14. The method of claim 1 wherein said period is a daily treatment for at least four weeks.
  • 15. A method according to claim 14 wherein said composition is applied daily for at least eight weeks.
  • 16. A method according to claim 1 wherein said composition is applied daily to the axillary area to reduce hair growth.
  • 17. A method according to claim 1 wherein said composition is added daily to a bath such that the water in said bath contacts the skin and hair follicles of a mammal.
  • 18. A method for inhibiting mammalian hair growth of hair in need thereof, comprising applying topically to hair follicles of a mammal, at least once daily for at least seven days from the beginning of a hair growth cycle an effective amount of a hair growth inhibiting topically active agent such that it penetrates into hair follicles on the skin of a mammal, said topically active agent comprising extract of soybeans having soy trypsin inhibitory activity, wherein after such application, hair growth is reduced and hair follicle and hair shaft size are reduced in comparison with the appearance of hair prior to applying said composition.
  • 19. A method according to claim 18 wherein said composition is applied to said hair for at least seven days from the beginning of the hair cycle.
  • 20. A method according to claim 18 wherein said composition is applied to said hair follicle for at least seven days from the beginning of the hair cycle.
  • 21. A method for reducing hair follicle and hair shaft size of mammalian hair in need thereof, comprising applying topically to hair follicles of a mammal, at least once daily for at least seven days from the beginning of a hair growth cycle an effective amount of a hair follicle and hair shaft size reducing topically active agent such that it penetrates into hair follicles on the skin of a mammal, said topically active agent comprising extract of soybeans having soy trypsin inhibitory activity, wherein after such application, hair follicle and hair shaft size are reduced in comparison with the appearance of hair prior to applying said composition.
  • 22. A method for reducing hair pigmentation of mammalian hair in need thereof, comprising applying topically to hair follicles of a mammal, at least once daily for at least seven days from the beginning of a hair growth cycle an effective amount of a hair pigmentation reducing topically active agent such that it penetrates into hair follicles on the skin of a mammal, said topically active agent comprising extract of soybeans having soy trypsin inhibitory activity, wherein after such application, hair pigmentation is reduced, hair growth is reduced and hair follicle and hair shaft size are reduced in comparison with the appearance of hair prior to applying said composition.
  • 23. A method according to claim 22 wherein said composition is applied to said hair for at least seven days from the beginning of the hair cycle.
  • 24. A method of reducing hair pigmentation, reducing hair growth, reducing hair follicles and reducing hair shaft size in mammalian hair in need thereof, comprising topically applying to hair follicles of a mammal, at least once daily for at least seven days from the beginning of a hair growth cycle an effective amount of a hair pigmentation, hair growth, hair follicle and hair shaft size reducing topically active composition comprising one or more compounds derived from soybeans having soy trypsin inhibitory activity wherein said compound consists essentially of soybean trypsin inhibitor wherein after such application, hair pigmentation is reduced, hair growth is reduced and hair follicle and hair shaft size are reduced in comparison with the appearance of hair prior to applying said composition.
  • 25. A method according to claim 24 wherein said composition is applied to said hair follicles for at least seven days from the beginning of the hair cycle.
  • 26. A method of reducing pseudofolliculitis barbae in mammalian hair in need thereof, comprising applying topically to hair follicles of a mammal, at least once daily for at least seven days from the beginning of a hair growth cycle, an effective amount of a hair growth-reducing and hair follicle and shaft size-reducing topically active composition comprising one or more compounds derived from one or more of a botanical family leguminosae, wherein said compounds contain at least one serine protease inhibitor consisting essentially of soybean trypsin inhibitor, wherein after daily application for at least seven days from the beginning of the hair cycle, hair growth, hair follicle and hair shaft size are reduced in comparison with the appearance of hair prior to applying said composition.
  • 27. A method to style and improve management of African type hair in mammalian hair in need thereof, comprising applying topically to hair follicles of a mammal, at least once daily for at least seven days from the beginning of a hair cycle an effective amount of a hair growth-reducing and hair follicle and shaft size-reducing topically active composition comprising one or more compounds derived from one or more of a botanical family leguminosae, wherein said compounds contain at least one serine protease inhibitor consisting essentially of soybean trypsin inhibitor, wherein after daily application for at least seven days from the beginning of the hair cycle, management of African type hair is improved in comparison with the appearance of hair prior to applying said composition.
  • 28. A method to for delaying hair growth and reducing hair visibility in sufferers of hirsutism, comprising applying topically to hair follicles of a mammal, at least once daily for at least seven days from the beginning of a hair cycle to hair on the skin of a sufferer of hirsutism an effective amount of a hair growth-reducing and hair follicle and shaft size-reducing topically active composition comprising one or more compounds derived from one or more of a botanical family leguminosae, wherein said compounds contain at least one serine protease inhibitor consisting essentially of soybean trypsin inhibitor, wherein after daily application for at least seven days from the beginning of the hair cycle, hair growth is delayed and hair visibility in sufferers of hirsutism is reduced in comparison with the appearance of hair prior to applying said composition.
  • 29. A method of reducing hair growth and reducing hair follicles and hair shaft size in mammalian hair in need thereof, comprising topically applying at least once daily for at least seven days from the beginning of a hair cycle to hair on the skin of a mammal an effective amount of a hair growth-reducing and hair follicle and shaft size-reducing topically active composition comprising one or more compounds derived from one or more of a botanical family leguminosae, wherein said compounds comprise at least one serine protease inhibitor consisting essentially of soybean trypsin inhibitor and Bowman-Birk Inhibitor, wherein after daily application for at least seven days from the beginning of the hair cycle, hair growth, hair follicle and hair shaft size are reduced in comparison with the appearance of hair prior to applying said composition.
  • 30. A method of reducing hair growth and reducing hair follicles and hair shaft size in mammalian hair in need thereof, comprising topically applying at least once daily for at least seven days from the beginning of a hair cycle to hair follicles on the skin of a mammal an effective amount of a hair growth-reducing and hair follicle and shaft size reducing topically active composition consisting essentially of soybean trypsin inhibitor, wherein after daily application for at least seven days from the beginning of the hair cycle, hair growth, hair follicles and hair shaft size are reduced in comparison with the appearance of hair prior to applying said composition.
Parent Case Info

This application claims the benefit of U.S. Provisional application 60/145,774, filed Jul. 27, 1999.

US Referenced Citations (296)
Number Name Date Kind
2876164 Wershaw Mar 1959 A
2924525 Kruse et al. Feb 1960 A
3097947 Kemmerer Jul 1963 A
3625976 Theimer Dec 1971 A
3755560 Dickert et al. Aug 1973 A
4007266 Choay Feb 1977 A
4056637 Hagiwara et al. Nov 1977 A
4151304 Evans Apr 1979 A
4190671 Vanstone et al. Feb 1980 A
4219569 Glenn Aug 1980 A
4223018 Belle Sep 1980 A
4254105 Fukuda Mar 1981 A
4272544 Cella et al. Jun 1981 A
4278570 Flom Jul 1981 A
4279930 Hall et al. Jul 1981 A
4297348 Frazier Oct 1981 A
4331692 Drevici et al. May 1982 A
4333927 Ofuchi et al. Jun 1982 A
4368187 Flom et al. Jan 1983 A
4370315 Greff et al. Jan 1983 A
4382960 Flom May 1983 A
4386067 Guillon May 1983 A
4421769 Dixon et al. Dec 1983 A
4427670 Ofuchi et al. Jan 1984 A
4434095 Chipens et al. Feb 1984 A
4437895 Koulbanis et al. Mar 1984 A
4439418 Möller et al. Mar 1984 A
4462981 Smith Jul 1984 A
4477434 Kosaka Oct 1984 A
4486448 Ser et al. Dec 1984 A
4488564 Grollier et al. Dec 1984 A
4512973 Dennis Apr 1985 A
4515778 Kastell May 1985 A
4524067 Arichi et al. Jun 1985 A
4537782 Millet et al. Aug 1985 A
4550035 Smith Oct 1985 A
4578267 Salamone Mar 1986 A
4584190 Tejima et al. Apr 1986 A
4603146 Kligman Jul 1986 A
4604281 Deckner et al. Aug 1986 A
4612192 Scheuffgen et al. Sep 1986 A
4690821 Smith et al. Sep 1987 A
4707293 Ferro Nov 1987 A
4727088 Scott et al. Feb 1988 A
4760096 Sakai et al. Jul 1988 A
4793991 Slimak Dec 1988 A
4824662 Hofmann Apr 1989 A
4834076 Millet et al. May 1989 A
4847267 Deckner et al. Jul 1989 A
4851214 Walters et al. Jul 1989 A
4859458 Salamone et al. Aug 1989 A
4867964 Forestier et al. Sep 1989 A
4871530 Grollier et al. Oct 1989 A
4885169 Gazzani Dec 1989 A
4895839 Bombardelli Jan 1990 A
4906457 Ryan Mar 1990 A
4943462 Komerska et al. Jul 1990 A
4960588 Hoshowski et al. Oct 1990 A
4960764 Figueroa, Jr. et al. Oct 1990 A
4970216 Deckner et al. Nov 1990 A
4971825 Kitazume et al. Nov 1990 A
4978528 Degre Dec 1990 A
5002761 Mueller et al. Mar 1991 A
5006337 Motitschke et al. Apr 1991 A
5032382 Grollier Jul 1991 A
5032400 Wiersum et al. Jul 1991 A
5043323 Bombardelli et al. Aug 1991 A
5057417 Hammonds et al. Oct 1991 A
5077038 Hofmann Dec 1991 A
5077040 Bergmann et al. Dec 1991 A
5104655 Bombardelli et al. Apr 1992 A
5110603 Rau May 1992 A
5116605 Alt May 1992 A
5118671 Bombardelli et al. Jun 1992 A
5130142 Wong et al. Jul 1992 A
5147859 Bombardelli et al. Sep 1992 A
5166139 Bombardelli et al. Nov 1992 A
5171577 Griat et al. Dec 1992 A
5179091 Lesieur et al. Jan 1993 A
5188823 Shapiro et al. Feb 1993 A
5192332 Lang et al. Mar 1993 A
5194252 Hofmann Mar 1993 A
5217717 Kennedy et al. Jun 1993 A
5229104 Sottery et al. Jul 1993 A
5231090 Hsia Jul 1993 A
5248495 Patterson et al. Sep 1993 A
5254331 Mausner Oct 1993 A
5260065 Mathur et al. Nov 1993 A
5270042 Whitham Dec 1993 A
5276058 Satoh et al. Jan 1994 A
5304482 Sambrook et al. Apr 1994 A
5306444 Kitamura et al. Apr 1994 A
5310734 Losch et al. May 1994 A
5322839 Voegeli Jun 1994 A
5352443 Kubo et al. Oct 1994 A
5362494 Zysman et al. Nov 1994 A
5364886 Löliger et al. Nov 1994 A
5393519 Dowell et al. Feb 1995 A
5397497 Jakobson et al. Mar 1995 A
5407675 Etemad-Moghadam Apr 1995 A
5411742 Sebag May 1995 A
5427814 Löliger Jun 1995 A
5428026 Colarow Jun 1995 A
5438044 Losch et al. Aug 1995 A
5439672 Zabotto et al. Aug 1995 A
5443839 Meybeck Aug 1995 A
5443840 Morancais et al. Aug 1995 A
5444092 Collins Aug 1995 A
5446605 Umehara Aug 1995 A
5466452 Whittle Nov 1995 A
5468473 Mullen Nov 1995 A
5498420 Mentrup Edgar et al. Mar 1996 A
5503832 De Stoutz Apr 1996 A
5505946 Kennedy et al. Apr 1996 A
5510391 Elson Apr 1996 A
5523308 Costanzo et al. Jun 1996 A
5539129 Zysman et al. Jul 1996 A
5545399 Lee et al. Aug 1996 A
5547661 Sun et al. Aug 1996 A
5554647 Perricone Sep 1996 A
5565493 Nakata et al. Oct 1996 A
5567420 McEleney et al. Oct 1996 A
5569663 Ribier et al. Oct 1996 A
5571503 Mausner Nov 1996 A
5578297 Mellul et al. Nov 1996 A
5589181 Bencsits Dec 1996 A
5595984 Blank Jan 1997 A
5597814 Blank Jan 1997 A
5601833 Ribier et al. Feb 1997 A
5603949 Meybeck et al. Feb 1997 A
5605894 Blank Feb 1997 A
5607666 Masson Mar 1997 A
5607692 Ribier et al. Mar 1997 A
5614180 Chung Mar 1997 A
5614215 Ribier et al. Mar 1997 A
5616572 Blank Apr 1997 A
5618522 Kaleta et al. Apr 1997 A
5620692 Potter et al. Apr 1997 A
5622690 Potter et al. Apr 1997 A
5626868 Morancais et al. May 1997 A
5629015 Ribier et al. May 1997 A
5629301 Blank May 1997 A
5631318 Ito et al. May 1997 A
5635165 Panitch Jun 1997 A
5637316 Ribier et al. Jun 1997 A
5639785 Kung Jun 1997 A
5641509 Gross et al. Jun 1997 A
5643583 Voultoury et al. Jul 1997 A
5643587 Scancarella et al. Jul 1997 A
5643601 Gross et al. Jul 1997 A
5650166 Ribier et al. Jul 1997 A
5652230 Blank Jul 1997 A
5653988 Gerber et al. Aug 1997 A
5660853 Hansenne-Richoux Aug 1997 A
5665367 Burger et al. Sep 1997 A
5670547 Milstein et al. Sep 1997 A
5674511 Kacher et al. Oct 1997 A
5676935 Mellul et al. Oct 1997 A
5676956 Duffy et al. Oct 1997 A
5679374 Fanchon et al. Oct 1997 A
5681571 Horngren et al. Oct 1997 A
5681852 Bissett Oct 1997 A
5683380 Eckhouse et al. Nov 1997 A
5683683 Scafidi Nov 1997 A
5686102 Gross et al. Nov 1997 A
5688763 Hammonds, Jr. et al. Nov 1997 A
5691327 Blank Nov 1997 A
5712356 Bothe et al. Jan 1998 A
5720772 Eckhouse Feb 1998 A
5723148 Love Mar 1998 A
5741496 Khaiat Apr 1998 A
5753612 Mitrani May 1998 A
5755814 Berg et al. May 1998 A
5762916 Ansmann et al. Jun 1998 A
5766628 Nürnberg et al. Jun 1998 A
5776917 Blank et al. Jul 1998 A
5780456 Blank Jul 1998 A
5780457 Blank Jul 1998 A
5780458 Blank Jul 1998 A
5780459 Blank et al. Jul 1998 A
5786345 Blank et al. Jul 1998 A
5786346 Blank Jul 1998 A
5789396 Blank et al. Aug 1998 A
5795879 Blank Aug 1998 A
5801163 Blank Sep 1998 A
5804216 Terren et al. Sep 1998 A
5807545 Coffindaffer et al. Sep 1998 A
5824702 Wei Oct 1998 A
5833965 Sun et al. Nov 1998 A
5834013 Ribier et al. Nov 1998 A
5834513 Ptchelintsev Nov 1998 A
5840717 Blank Nov 1998 A
5843907 Sakai et al. Dec 1998 A
5843926 Blank Dec 1998 A
5863546 Swinehart Jan 1999 A
5869031 Tarroux et al. Feb 1999 A
5869470 Blank et al. Feb 1999 A
5871480 Tankovich Feb 1999 A
5871743 Chajuss Feb 1999 A
5871823 Anders et al. Feb 1999 A
5880314 Shinomiya et al. Mar 1999 A
5885593 Epstein Mar 1999 A
5885596 Parab Mar 1999 A
5885600 Blum et al. Mar 1999 A
5885617 Jordan Mar 1999 A
5885948 Glenn, Jr. et al. Mar 1999 A
5888522 Pickart Mar 1999 A
5908618 Lorant Jun 1999 A
5912175 Wille, Jr. Jun 1999 A
5916577 Golz et al. Jun 1999 A
5928654 Duranton Jul 1999 A
5928658 Kishida et al. Jul 1999 A
5928889 Bakich et al. Jul 1999 A
6750229 Seiberg et al. Jul 1999 B2
5936052 Bothe et al. Aug 1999 A
5942479 Frankenbach et al. Aug 1999 A
5945095 Mougin et al. Aug 1999 A
5945109 Schmidt et al. Aug 1999 A
5952373 Lanzendörfer et al. Sep 1999 A
5958387 Bara et al. Sep 1999 A
5958946 Styczynski et al. Sep 1999 A
5961980 Kennedy Oct 1999 A
5962015 Delrieu et al. Oct 1999 A
5962441 Blank Oct 1999 A
5965153 Allen Oct 1999 A
5972355 Knight et al. Oct 1999 A
5981450 Fabry et al. Nov 1999 A
5985338 Suh et al. Nov 1999 A
5985809 Frankenbach et al. Nov 1999 A
5985842 Miljkovic Nov 1999 A
5990291 Waggle et al. Nov 1999 A
6004915 Elliott et al. Dec 1999 A
6013250 Cannell et al. Jan 2000 A
6013255 Edens et al. Jan 2000 A
6017549 Knight et al. Jan 2000 A
6017893 Segelman Jan 2000 A
6018001 Hiratani et al. Jan 2000 A
6019962 Rabe et al. Feb 2000 A
6030931 Vinski et al. Feb 2000 A
6033680 Dixon et al. Mar 2000 A
6045548 Furumoto et al. Apr 2000 A
6045779 Mueller et al. Apr 2000 A
6048520 Hoshowski Apr 2000 A
6051602 Bissett Apr 2000 A
6054137 Breton et al. Apr 2000 A
6060070 Gorbach May 2000 A
6063398 Gueret May 2000 A
6080393 Liu et al. Jun 2000 A
6093411 Bissett Jul 2000 A
6096327 Lezdey et al. Aug 2000 A
6126933 Warne et al. Oct 2000 A
6139899 Matsuura et al. Oct 2000 A
6180662 Lanzendörfer et al. Jan 2001 B1
6183761 Bissett et al. Feb 2001 B1
6183762 Deckers et al. Feb 2001 B1
6555143 Miller et al. Feb 2001 B2
6217572 Tobinick Apr 2001 B1
6248350 Mori et al. Jun 2001 B1
6261603 McElwain Jul 2001 B1
6272883 Bruder et al. Aug 2001 B2
6273885 Koop et al. Aug 2001 B1
6323219 Costanzo Nov 2001 B1
6358242 Cecchetti Mar 2002 B1
6365802 Kridl Apr 2002 B2
6399083 Pillai et al. Jun 2002 B1
6413546 He et al. Jul 2002 B1
6423747 Lanzendörfer Jul 2002 B1
6433025 Lorenz Aug 2002 B1
6447809 Krumhar et al. Sep 2002 B1
6461348 Bertan et al. Oct 2002 B1
6461627 Ichioka Oct 2002 B1
6485484 Connors et al. Nov 2002 B1
6544255 Stewart Apr 2003 B2
6551606 Golz-Berner et al. Apr 2003 B1
6558656 Mann May 2003 B2
20020034489 Wiegland Mar 2002 A1
20020035046 Lukenbach Mar 2002 A1
20020065300 Seiberg et al. May 2002 A1
20020160061 Saliou et al. Oct 2002 A1
20020160062 Liu et al. Oct 2002 A1
20020160063 Miller et al. Oct 2002 A1
20020182166 Martin Dec 2002 A1
20020192313 Saliou et al. Dec 2002 A1
20020197244 Seiberg et al. Dec 2002 A1
20030064049 Seiberg et al. Apr 2003 A1
20030224075 Liu et al. Dec 2003 A1
20040009142 Zambaux et al. Jan 2004 A1
20040062731 Seiberg et al. Apr 2004 A1
20040063593 Wu et al. Apr 2004 A1
20040067244 Friedman Apr 2004 A1
20050008665 Batzer Jan 2005 A1
20050019279 Goppel Jan 2005 A1
20050281776 Courcoux Dec 2005 A1
20070009459 Magnant Jan 2007 A1
20070041931 Morelli Feb 2007 A1
20070160564 Liu et al. Jul 2007 A1
Foreign Referenced Citations (200)
Number Date Country
199870006 May 1998 AU
1081899 Feb 1994 CN
1 094 279 Nov 1994 CN
1146876 Apr 1997 CN
1166960 Dec 1997 CN
4432947 Mar 1996 DE
19634206 Mar 1998 DE
19818849 Oct 1998 DE
0421021 Jun 1989 EP
0 341 745 Nov 1989 EP
0 393 532 Oct 1990 EP
0 476 311 Mar 1992 EP
0473502 Mar 1992 EP
0 508 886 Oct 1992 EP
0 532 465 Mar 1993 EP
0 574 352 Dec 1993 EP
0 581 624 Feb 1994 EP
0 581 624 Feb 1994 EP
0 582 239 Feb 1994 EP
0 582 239 Feb 1994 EP
0 643 083 Mar 1995 EP
0 643 960 Mar 1995 EP
0 655 470 May 1995 EP
0273202 Jun 1995 EP
0 661 037 Jul 1995 EP
0707851 Apr 1996 EP
0707851 Apr 1996 EP
0 713 106 May 1996 EP
0 758 687 Feb 1997 EP
0774249 May 1997 EP
0 814 116 Dec 1997 EP
0811595 Dec 1997 EP
0 963 761 Dec 1999 EP
1 074 240 Feb 2001 EP
1077 063 Feb 2001 EP
1 192 938 Apr 2002 EP
1 210 946 Jun 2002 EP
1 236 402 Sep 2002 EP
1 236 465 Sep 2002 EP
1 348 441 Oct 2003 EP
1 647 278 Apr 2006 EP
2 596 986 Oct 1987 FR
2 641 696 Jul 1990 FR
2 685 202 Jun 1993 FR
2803747 Jul 2001 FR
2 811 226 Jan 2002 FR
1098951 Jan 1968 GB
58-225003 Jun 1982 JP
58225004 Dec 1983 JP
59187756 Oct 1984 JP
60061513 Apr 1985 JP
63-68512 Sep 1986 JP
6-2036304 Feb 1987 JP
62 036304 Feb 1987 JP
62036304 Feb 1987 JP
63-316711 Jun 1987 JP
196106 Oct 1987 JP
63-96120 Apr 1988 JP
63135310 Jun 1988 JP
63-227515 Sep 1988 JP
1093519 Apr 1989 JP
1096106 Apr 1989 JP
3-127713 Oct 1989 JP
02-286165 Nov 1990 JP
5-320061 May 1991 JP
5-25027 Jul 1991 JP
5-320024 May 1992 JP
4-169514 Jun 1992 JP
04283518 Oct 1992 JP
5015574 Jan 1993 JP
5-25027 Feb 1993 JP
05025027 Feb 1993 JP
5114905 May 1993 JP
5-213729 Aug 1993 JP
5-246932 Sep 1993 JP
899891 Jan 1994 JP
6145061 May 1994 JP
7304655 May 1994 JP
812560 Jun 1994 JP
8-020597 Jul 1994 JP
6192085 Jul 1994 JP
06256156 Sep 1994 JP
6256156 Sep 1994 JP
7010772 Jan 1995 JP
925212 Jul 1995 JP
925214 Jul 1995 JP
7196527 Aug 1995 JP
7196529 Aug 1995 JP
7304655 Nov 1995 JP
08012531 Jan 1996 JP
8012560 Jan 1996 JP
8040824 Feb 1996 JP
8059450 Mar 1996 JP
08081336 Mar 1996 JP
8143442 Jun 1996 JP
408143442 Jun 1996 JP
8333260 Dec 1996 JP
09 025212 Jan 1997 JP
9025212 Jan 1997 JP
9025213 Jan 1997 JP
9025214 Jan 1997 JP
090 59166 Mar 1997 JP
90 59166 Mar 1997 JP
9077638 Mar 1997 JP
9176033 Jul 1997 JP
10-046196 Feb 1998 JP
10-139654 May 1998 JP
10120542 May 1998 JP
10120542 May 1998 JP
10139639 May 1998 JP
10139654 May 1998 JP
10-175815 Jun 1998 JP
410226642 Aug 1998 JP
11322548 Nov 1999 JP
11346695 Dec 1999 JP
200191459 Jul 2000 JP
2000-351720 Dec 2000 JP
2000 302678 Oct 2001 JP
2001-271096 Oct 2001 JP
2004-000019 Jan 2004 JP
92-8851 Oct 1992 KR
92-8853 Oct 1992 KR
2066992 Sep 1996 RU
WO 8707838 Dec 1987 WO
WO 9104283 Apr 1991 WO
WO 9107166 May 1991 WO
WO 9209639 Jun 1992 WO
WO 9209650 Jun 1992 WO
WO 9406485 Mar 1994 WO
WO 9407462 Apr 1994 WO
WO 9504609 Feb 1995 WO
WO 9509002 Apr 1995 WO
WO 9509011 Apr 1995 WO
WO 9524885 Sep 1995 WO
WO 9609806 Apr 1996 WO
WO 9619483 Jun 1996 WO
WO 9619491 Jun 1996 WO
WO 9624371 Aug 1996 WO
WO 9624392 Aug 1996 WO
WO 9629050 Sep 1996 WO
WO 9630035 Oct 1996 WO
WO 9630396 Oct 1996 WO
WO 9631194 Oct 1996 WO
WO 9637497 Nov 1996 WO
WO 9640121 Dec 1996 WO
WO 9640199 Dec 1996 WO
WO 9711033 Mar 1997 WO
WO 9718904 May 1997 WO
WO 9735998 Oct 1997 WO
WO 9739733 Oct 1997 WO
WO 9801107 Jan 1998 WO
WO 9802134 Jan 1998 WO
WO 9802138 Jan 1998 WO
WO 9805333 Feb 1998 WO
WO 9808503 Mar 1998 WO
WO 9809987 Mar 1998 WO
WO 9817246 Apr 1998 WO
WO 9833089 Jul 1998 WO
WO 9849153 Nov 1998 WO
WO 9900110 Jan 1999 WO
WO 9904752 Feb 1999 WO
WO 9909065 Feb 1999 WO
WO 9915917 Apr 1999 WO
WO 9924003 May 1999 WO
WO 9930729 Jun 1999 WO
WO 9936050 Jul 1999 WO
WO 9939682 Aug 1999 WO
WO 9957178 Nov 1999 WO
WO 0015188 Mar 2000 WO
WO 0043049 Jul 2000 WO
WO 0051554 Sep 2000 WO
WO 0051554 Sep 2000 WO
WO 0062740 Oct 2000 WO
WO 0062740 Oct 2000 WO
WO 0062741 Oct 2000 WO
WO 0062741 Oct 2000 WO
WO 0062743 Oct 2000 WO
WO 0062743 Oct 2000 WO
WO 0062744 Oct 2000 WO
WO 0062745 Oct 2000 WO
WO 00162744 Oct 2000 WO
WO 0069404 Nov 2000 WO
WO 0069406 Nov 2000 WO
WO 0069407 Nov 2000 WO
WO 0069408 Nov 2000 WO
WO 0074699 Dec 2000 WO
WO 0076458 Dec 2000 WO
WO 0129163 Apr 2001 WO
WO 0134099 May 2001 WO
WO 0134909 May 2001 WO
WO 0135920 May 2001 WO
WO 02 07697 Jan 2002 WO
WO 0207697 Jan 2002 WO
WO 02064104 Aug 2002 WO
WO 02067988 Sep 2002 WO
WO 02074280 Sep 2002 WO
WO 03032941 Apr 2003 WO
WO 03039502 May 2003 WO
WO 2004022024 Mar 2004 WO
WO 2005097216 Oct 2005 WO
Provisional Applications (1)
Number Date Country
60145774 Jul 1999 US